ClinicalTrials.gg
CompletedNCT02935634FRACTION-GCUpdated Jun 9, 2023Results posted

A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer

A Phase 2 interventional study of Nivolumab and Ipilimumab in Advanced Gastric Cancer, sponsored by Bristol-Myers Squibb. Completed at 35 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-09.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
190
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies in Stomach Neoplasms by Bristol-Myers Squibb — 1 open to participants now, 4 under way, 1 of them phase 3. Stomach Neoplasms · Bristol-Myers Squibb.

Enrollment
5th of 10
190 · median 143
Started
2016
with 1 other
Phase 2
4 of 14
none open now
Registered
6th of 14
by date

Among the 14 studies in Stomach Neoplasms by Bristol-Myers Squibb, this one is the 5th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2016, is one of 4 in phase 2, and was the 6th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 993 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

1 of the 14 studies in Stomach Neoplasms by Bristol-Myers Squibb is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Stomach Neoplasms by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the preliminary efficacy, safety, and tolerability of Nivolumab in combination with Ipilimumab or other treatment therapies in participants with advanced gastric cancer.

03

Conditions studied

  • Advanced Gastric Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Inoperable, advanced or esophageal cancer (EC), gastric cancer (GC) or gastroesophageal junction (GEJ) carcinoma and have confirmed predominant adenocarcinoma and/or squamous carcinoma
  • (ECOG) performance status ≤ 1
  • At least 1 lesion with

Exclusion criteria

Exclusion Criteria:

  • -positive tumor and previously untreated with trastuzumab
  • Suspected, known or progressive central nervous system
  • Other active requiring concurrent intervention
  • Active, known or suspected disease

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
190 participants (actual)

Study arms

  • Active comparator
    Nivolumab + Ipilimumab

    Biological: Nivolumab · Biological: Ipilimumab

  • Experimental
    Nivolumab + Relatlimab

    Biological: Nivolumab · Biological: Relatlimab

  • Experimental
    Nivolumab + BMS-986205

    Biological: Nivolumab · Biological: BMS-986205

  • Experimental
    Nivolumab + Rucaparib

    Biological: Nivolumab · Drug: Rucaparib

  • Experimental
    Ipilimumab + Rucaparib

    Biological: Ipilimumab · Drug: Rucaparib

  • Experimental
    Nivolumab + Ipilimumab + Rucaparib

    Biological: Nivolumab · Biological: Ipilimumab · Drug: Rucaparib

Interventions

  • BiologicalNivolumab

    Specified dose on specified days

    Also known as: Opdivo, BMS-936558

  • BiologicalIpilimumab

    Specified dose on specified days

    Also known as: Yervoy, BMS-734016

  • BiologicalRelatlimab

    Specified dose on specified days

    Also known as: BMS-986016

  • BiologicalBMS-986205

    Specified dose on specified days

  • Specified dose on specified days

    Also known as: Rubraca

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) by Investigator

    ORR is the percent of participants whose best overall response (BOR) is complete response (CR) or partial response (PR). BOR is the best response from the start of the study treatment until objectively documented progression per RECIST v1.1 or subsequent anticancer therapy, whichever occurs first. CR is the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) have reduction in short axis to \<10 mm. PR is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. The Response Evaluation Criteria in Solid Tumors (RECIST) is a standard way to measure the response of a tumor to treatment. CR+PR, confidence interval based on Clopper and Pearson method.

    Time frame: From first dose of study treatment until progression or subsequent anticancer therapy, whichever occurs first (up to approximately 65 months)

  2. Median Duration of Response (DOR)

    Duration of Response (DOR) is the time between the date of first response and the date of first documented disease progression as determined by RECIST 1.1 or death due to any cause, whichever occurred first. Complete Response (CR) is the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR) is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Median computed using Kaplan -Meier method.

    Time frame: From first dose to date of first documented tumor progression or death due to any cause, whichever occurred first (up to approximately 65 months)

  3. Kaplan-Meier Analysis of Progression Free Survival Rate (PFSR) at 24 Weeks

    The PFSR at 24 weeks is defined as the proportion of treated participants remaining progression free and surviving at 24 weeks since the first dosing date. Progressive Disease (PD) is at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Point estimates are derived from Kaplan-Meier analyses, the 95% CIs are derived from Greenwood formula.

    Time frame: 24 weeks after first dose

Secondary outcomes

  1. Number of Participants With AEs, SAEs, AEs Leading to Discontinuation, and Death

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires inpatient hospitalization or causes prolongation of existing hospitalization.

    Time frame: From first dose to 100 days after last dose of study therapy (assessed up to approximately 30 months)

  2. Number of Participants With Laboratory Abnormalities in Specific Thyroid Tests

    The number of participants with laboratory abnormalities in specific thyroid tests based on US conventional units. TSH = Thyroid Stimulating Hormone LLN = Lower Limit of Normal ULN = Upper Limit of Normal.

    Time frame: From first dose to 100 days after last dose of study therapy (approximately 30 months)

  3. Number of Participants With Laboratory Abnormalities in Specific Liver Tests

    The number of participants with laboratory abnormalities in specific liver tests based on US conventional units. ALT = Alanine Aminotransferase AST = Aspartate Aminotransferase ULN = Upper Limit of Normal

    Time frame: From first dose to 100 days after last dose of study therapy (approximately 30 months)

07

Results

Posted Jun 9, 2023

Participant flow

Randomization
Participant flow — Randomization
MilestoneNivolumab + IpilimumabNivolumab + BMS-986016Nivolumab + BMS-986205Nivolumab + RucaparibIpilimumab + RucaparibNivolumab + Ipilimumab + Rucaparib
Started425462121010
Randomized to track 1232238786
Randomized to track 2193224524
Completed405059121010
Not completed243000
Withdrew: Participant withdrew consent010000
Withdrew: Death211000
Withdrew: Other reasons022000
Treatment: Track 1
Participant flow — Treatment: Track 1
MilestoneNivolumab + IpilimumabNivolumab + BMS-986016Nivolumab + BMS-986205Nivolumab + RucaparibIpilimumab + RucaparibNivolumab + Ipilimumab + Rucaparib
Started232038786
Re-randomized to track 2233000
Completed111000
Not completed221937786
Withdrew: Disease progression151728462
Withdrew: Adverse event unrelated to study drug112303
Withdrew: Lost to follow-up100000
Withdrew: Study drug toxicity213001
Withdrew: Participant request to discontinue treatment101010
Withdrew: Participant withdrew consent201010
Withdrew: Other reasons002000
Treatment: Track 2
Participant flow — Treatment: Track 2
MilestoneNivolumab + IpilimumabNivolumab + BMS-986016Nivolumab + BMS-986205Nivolumab + RucaparibIpilimumab + RucaparibNivolumab + Ipilimumab + Rucaparib
Started233622624
No pre-randomization173021524
Re-randomized from track 1 nivolumab + relatlimab101100
Re-randomized from track 1 nivolumab + ipilimumab210000
Re-randomized from track 2 nivolumab + relatlimab020000
Re-randomized from track 2 nivolumab + bms986205300000
Previously un-treated but re-randomized010000
Re-randomized from track 2 nivolumab + ipilimumab020000
Completed120100
Not completed223422524
Withdrew: Disease progression132620514
Withdrew: Adverse event unrelated to study drug220000
Withdrew: Study drug toxicity730000
Withdrew: Participant request to discontinue treatment021000
Withdrew: Participant withdrew consent011010

Outcome measures

PrimaryObjective Response Rate (ORR) by Investigator

ORR is the percent of participants whose best overall response (BOR) is complete response (CR) or partial response (PR). BOR is the best response from the start of the study treatment until objectively documented progression per RECIST v1.1 or subsequent anticancer therapy, whichever occurs first. CR is the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) have reduction in short axis to \<10 mm. PR is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. The Response Evaluation Criteria in Solid Tumors (RECIST) is a standard way to measure the response of a tumor to treatment. CR+PR, confidence interval based on Clopper and Pearson method.

Time frame:
From first dose of study treatment until progression or subsequent anticancer therapy, whichever occurs first (up to approximately 65 months)
Reported as:
Number · Percent of participants
Objective Response Rate (ORR) by Investigator
Percent of participantsTrack 1: Nivolumab + IpilimumabTrack 1: Nivolumab + BMS-986016Track 1: Nivolumab + BMS-986205Track 1: Nivolumab + RucaparibTrack 1: Ipilimumab + RucaparibTrack 1: Nivolumab + Ipilimumab + RucaparibTrack 2: Nivolumab + IpilimumabTrack 2: Nivolumab + BMS-986016Track 2: Nivolumab + BMS-986205Track 2: Nivolumab + RucaparibTrack 2: Ipilimumab + RucaparibTrack 2: Nivolumab + Ipilimumab + Rucaparib
Objective Response Rate (ORR) by Investigator4.3 (0.1 to 21.9)5.0 (0.1 to 24.9)13.2 (4.4 to 28.1)0 (0.0 to 41.0)0 (0.0 to 36.9)16.7 (0.4 to 64.1)8.7 (1.1 to 28.0)5.6 (0.7 to 18.7)0 (0.0 to 15.4)0 (0.0 to 45.9)0 (0.0 to 84.2)0 (0.0 to 60.2)
PrimaryMedian Duration of Response (DOR)

Duration of Response (DOR) is the time between the date of first response and the date of first documented disease progression as determined by RECIST 1.1 or death due to any cause, whichever occurred first. Complete Response (CR) is the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR) is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Median computed using Kaplan -Meier method.

Time frame:
From first dose to date of first documented tumor progression or death due to any cause, whichever occurred first (up to approximately 65 months)
Reported as:
Median · Weeks
Median Duration of Response (DOR)
WeeksTrack 1: Nivolumab + IpilimumabTrack 1: Nivolumab + BMS-986016Track 1: Nivolumab + BMS-986205Track 1: Nivolumab + RucaparibTrack 1: Ipilimumab + RucaparibTrack 1: Nivolumab + Ipilimumab + RucaparibTrack 2: Nivolumab + IpilimumabTrack 2: Nivolumab + BMS-986016Track 2: Nivolumab + BMS-986205Track 2: Nivolumab + RucaparibTrack 2: Ipilimumab + RucaparibTrack 2: Nivolumab + Ipilimumab + Rucaparib
Median Duration of Response (DOR)156.0 (156.0 to 156.0)NA (113.4 to 113.4)NA (37.3 to 144.0)——NA (0.1 to 0.1)14.71 (0.1 to 14.71)16.86 (8.1 to 25.6)————
PrimaryKaplan-Meier Analysis of Progression Free Survival Rate (PFSR) at 24 Weeks

The PFSR at 24 weeks is defined as the proportion of treated participants remaining progression free and surviving at 24 weeks since the first dosing date. Progressive Disease (PD) is at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Point estimates are derived from Kaplan-Meier analyses, the 95% CIs are derived from Greenwood formula.

Time frame:
24 weeks after first dose
Reported as:
Number · Proportion of participants
Kaplan-Meier Analysis of Progression Free Survival Rate (PFSR) at 24 Weeks
Proportion of participantsTrack 1: Nivolumab + IpilimumabTrack 1: Nivolumab + BMS-986016Track 1: Nivolumab + BMS-986205Track 1: Nivolumab + RucaparibTrack 1: Ipilimumab + RucaparibTrack 1: Nivolumab + Ipilimumab + RucaparibTrack 2: Nivolumab + IpilimumabTrack 2: Nivolumab + BMS-986016Track 2: Nivolumab + BMS-986205Track 2: Nivolumab + RucaparibTrack 2: Ipilimumab + RucaparibTrack 2: Nivolumab + Ipilimumab + Rucaparib
Kaplan-Meier Analysis of Progression Free Survival Rate (PFSR) at 24 WeeksNA (NA to NA)NA (NA to NA)0.240 (0.114 to 0.393)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)0.170 (0.063 to 0.322)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryNumber of Participants With AEs, SAEs, AEs Leading to Discontinuation, and Death

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires inpatient hospitalization or causes prolongation of existing hospitalization.

Time frame:
From first dose to 100 days after last dose of study therapy (assessed up to approximately 30 months)
Reported as:
Number · Participants
Number of Participants With AEs, SAEs, AEs Leading to Discontinuation, and Death
ParticipantsTrack 1: Nivolumab + IpilimumabTrack 1: Nivolumab + BMS-986016Track 1: Nivolumab + BMS-986205Track 1: Nivolumab + RucaparibTrack 1: Ipilimumab + RucaparibTrack 1: Nivolumab + Ipilimumab + RucaparibTrack 2: Nivolumab + IpilimumabTrack 2: Nivolumab + BMS-986016Track 2: Nivolumab + BMS-986205Track 2: Nivolumab + RucaparibTrack 2: Ipilimumab + RucaparibTrack 2: Nivolumab + Ipilimumab + Rucaparib
Adverse Events (AEs)232038786233622624
Serious Adverse Events (SAEs)191524564172412423
AEs Leading to Discontinuation97113441082010
Death191526754192613323
SecondaryNumber of Participants With Laboratory Abnormalities in Specific Thyroid Tests

The number of participants with laboratory abnormalities in specific thyroid tests based on US conventional units. TSH = Thyroid Stimulating Hormone LLN = Lower Limit of Normal ULN = Upper Limit of Normal.

Time frame:
From first dose to 100 days after last dose of study therapy (approximately 30 months)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities in Specific Thyroid Tests
ParticipantsTrack 1: Nivolumab + IpilimumabTrack 1: Nivolumab + BMS-986016Track 1: Nivolumab + BMS-986205Track 1: Nivolumab + RucaparibTrack 1: Ipilimumab + RucaparibTrack 1: Nivolumab + Ipilimumab + RucaparibTrack 2: Nivolumab + IpilimumabTrack 2: Nivolumab + BMS-986016Track 2: Nivolumab + BMS-986205Track 2: Nivolumab + RucaparibTrack 2: Ipilimumab + RucaparibTrack 2: Nivolumab + Ipilimumab + Rucaparib
TSH > ULN4461111155011
TSH > ULN WITH TSH <= ULN AT BASELINE334011614010
TSH >ULN WITH ATLEAST ONE FT3/FT4 TEST VALUE <LLN122011522001
TSH >ULN WITH ALL OTHER FT3/FT4 TEST VALUES >= LLN111100320000
TSH > ULN WITH FT3/FT4 TEST MISSING213000313010
TSH < LLN125000460000
TSH <LLN WITH TSH >= LLN AT BASELINE013000350000
TSH <LLN WITH ATLEAST ONE FT3/FT4 TEST VALUE > ULN102000320000
TSH <LLN WITH ALL OTHER FT3/FT4 TEST VALUES <= ULN021000100000
TSH < LLN WITH FT3/FT4 TEST MISSING002000040000
SecondaryNumber of Participants With Laboratory Abnormalities in Specific Liver Tests

The number of participants with laboratory abnormalities in specific liver tests based on US conventional units. ALT = Alanine Aminotransferase AST = Aspartate Aminotransferase ULN = Upper Limit of Normal

Time frame:
From first dose to 100 days after last dose of study therapy (approximately 30 months)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities in Specific Liver Tests
ParticipantsTrack 1: Nivolumab + IpilimumabTrack 1: Nivolumab + BMS-986016Track 1: Nivolumab + BMS-986205Track 1: Nivolumab + RucaparibTrack 1: Ipilimumab + RucaparibTrack 1: Nivolumab + Ipilimumab + RucaparibTrack 2: Nivolumab + IpilimumabTrack 2: Nivolumab + BMS-986016Track 2: Nivolumab + BMS-986205Track 2: Nivolumab + RucaparibTrack 2: Ipilimumab + RucaparibTrack 2: Nivolumab + Ipilimumab + Rucaparib
ALT OR AST > 3XULN665121622310
ALT OR AST> 5XULN323011410010
ALT OR AST> 10XULN212000300010
ALT OR AST > 20XULN001000100000
TOTAL BILIRUBIN > 2XULN230111313100
ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 1 DAY220111200100
ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 30 DAYS220111200100

Adverse events

Collected over Participants were assessed for all-cause mortality from their randomization until their study completion (up to approximately 65 months). SAEs and other AEs were assessed from first dose to 100 days after last dose of study therapy (up to approximately 30 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Track 1: Nivolumab + Ipilimumab19/23 (82.6%)19/23 (82.6%)21/23 (91.3%)
Track 1: Nivolumab + BMS-98601615/23 (65.2%)15/20 (75%)20/20 (100%)
Track 1: Nivolumab + BMS-98620526/39 (66.7%)24/38 (63.2%)38/38 (100%)
Track 1: Nivolumab + Rucaparib7/7 (100%)5/7 (71.4%)7/7 (100%)
Track 1: Ipilimumab + Rucaparib5/8 (62.5%)6/8 (75%)8/8 (100%)
Track 1: Nivolumab + Ipilimumab + Rucaparib4/6 (66.7%)4/6 (66.7%)6/6 (100%)
Track 2: Nivolumab + Ipilimumab19/28 (67.9%)17/23 (73.9%)23/23 (100%)
Track 2: Nivolumab + BMS-98601626/41 (63.4%)24/36 (66.7%)34/36 (94.4%)
Track 2: Nivolumab + BMS-98620513/25 (52%)12/22 (54.5%)21/22 (95.5%)
Track 2: Nivolumab + Rucaparib3/6 (50%)4/6 (66.7%)6/6 (100%)
Track 2: Ipilimumab + Rucaparib2/2 (100%)2/2 (100%)2/2 (100%)
Track 2: Nivolumab + Ipilimumab + Rucaparib3/4 (75%)3/4 (75%)4/4 (100%)
Most frequent serious events
Showing 10 of 113
Most frequent serious events
EventTrack 1: Nivolumab + IpilimumabTrack 1: Nivolumab + BMS-986016Track 1: Nivolumab + BMS-986205Track 1: Nivolumab + RucaparibTrack 1: Ipilimumab + RucaparibTrack 1: Nivolumab + Ipilimumab + RucaparibTrack 2: Nivolumab + IpilimumabTrack 2: Nivolumab + BMS-986016Track 2: Nivolumab + BMS-986205Track 2: Nivolumab + RucaparibTrack 2: Ipilimumab + RucaparibTrack 2: Nivolumab + Ipilimumab + Rucaparib
PyrexiaGeneral disorders1/230/201/380/70/80/60/230/360/221/61/20/4
HepatitisHepatobiliary disorders0/230/200/380/70/80/60/230/360/220/61/20/4
PneumoniaInfections and infestations1/230/202/380/70/80/60/230/360/221/61/20/4
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)11/236/2011/380/73/80/65/239/368/222/61/22/4
General physical health deteriorationGeneral disorders0/230/200/382/71/80/60/230/360/220/60/20/4
AnaemiaBlood and lymphatic system disorders1/233/202/380/70/80/62/231/360/220/60/21/4
Skin bacterial infectionInfections and infestations0/230/200/380/70/80/60/230/360/220/60/21/4
Acute kidney injuryRenal and urinary disorders0/230/201/380/70/80/60/230/360/220/60/21/4
AspirationRespiratory, thoracic and mediastinal disorders3/230/200/380/70/80/60/230/360/220/60/21/4
DyspnoeaRespiratory, thoracic and mediastinal disorders0/231/202/380/70/80/61/230/362/220/60/21/4
Most frequent other events
Showing 10 of 158
Most frequent other events
EventTrack 1: Nivolumab + IpilimumabTrack 1: Nivolumab + BMS-986016Track 1: Nivolumab + BMS-986205Track 1: Nivolumab + RucaparibTrack 1: Ipilimumab + RucaparibTrack 1: Nivolumab + Ipilimumab + RucaparibTrack 2: Nivolumab + IpilimumabTrack 2: Nivolumab + BMS-986016Track 2: Nivolumab + BMS-986205Track 2: Nivolumab + RucaparibTrack 2: Ipilimumab + RucaparibTrack 2: Nivolumab + Ipilimumab + Rucaparib
FatigueGeneral disorders13/2311/2023/382/75/82/610/2322/3611/225/62/22/4
NauseaGastrointestinal disorders8/2310/2017/384/74/82/610/239/366/224/60/22/4
Alanine aminotransferase increasedInvestigations0/235/207/381/73/84/65/233/362/221/61/20/4
Aspartate aminotransferase increasedInvestigations0/235/208/382/73/84/65/233/364/221/61/21/4
DiarrhoeaGastrointestinal disorders2/235/207/384/71/82/67/237/363/222/61/21/4
TachycardiaCardiac disorders0/230/201/380/70/80/60/230/360/220/61/20/4
Abdominal painGastrointestinal disorders7/237/2011/382/71/82/67/236/361/223/60/22/4
ConstipationGastrointestinal disorders3/235/209/382/72/82/67/236/364/222/61/21/4
IleusGastrointestinal disorders0/230/200/380/70/80/60/230/360/220/61/20/4
Large intestinal obstructionGastrointestinal disorders0/230/200/380/70/80/60/230/360/220/61/20/4

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Track 1: Nivolumab + IpilimumabTrack 1: Nivolumab + BMS-986016Track 1: Nivolumab + BMS-986205Track 1: Nivolumab + RucaparibTrack 1: Ipilimumab + RucaparibTrack 1: Nivolumab + Ipilimumab + RucaparibTrack 2: Nivolumab + IpilimumabTrack 2: Nivolumab + BMS-986016Track 2: Nivolumab + BMS-986205Track 2: Nivolumab + RucaparibTrack 2: Ipilimumab + RucaparibTrack 2: Nivolumab + Ipilimumab + RucaparibTotal
Mean62.0 ± 11.058.1 ± 12.660.6 ± 12.958.1 ± 10.457.4 ± 13.959.5 ± 6.755.9 ± 12.061.8 ± 11.864.2 ± 9.258.0 ± 16.257.0 ± 2.853.0 ± 16.460.1 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)Track 1: Nivolumab + IpilimumabTrack 1: Nivolumab + BMS-986016Track 1: Nivolumab + BMS-986205Track 1: Nivolumab + RucaparibTrack 1: Ipilimumab + RucaparibTrack 1: Nivolumab + Ipilimumab + RucaparibTrack 2: Nivolumab + IpilimumabTrack 2: Nivolumab + BMS-986016Track 2: Nivolumab + BMS-986205Track 2: Nivolumab + RucaparibTrack 2: Ipilimumab + RucaparibTrack 2: Nivolumab + Ipilimumab + RucaparibTotal
Female541404227910048
Male181824744172515424142
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Track 1: Nivolumab + IpilimumabTrack 1: Nivolumab + BMS-986016Track 1: Nivolumab + BMS-986205Track 1: Nivolumab + RucaparibTrack 1: Ipilimumab + RucaparibTrack 1: Nivolumab + Ipilimumab + RucaparibTrack 2: Nivolumab + IpilimumabTrack 2: Nivolumab + BMS-986016Track 2: Nivolumab + BMS-986205Track 2: Nivolumab + RucaparibTrack 2: Ipilimumab + RucaparibTrack 2: Nivolumab + Ipilimumab + RucaparibTotal
Hispanic or Latino1010001010004
Not Hispanic or Latino131717224142517322118
Unknown or Not Reported952056247620268
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Track 1: Nivolumab + IpilimumabTrack 1: Nivolumab + BMS-986016Track 1: Nivolumab + BMS-986205Track 1: Nivolumab + RucaparibTrack 1: Ipilimumab + RucaparibTrack 1: Nivolumab + Ipilimumab + RucaparibTrack 2: Nivolumab + IpilimumabTrack 2: Nivolumab + BMS-986016Track 2: Nivolumab + BMS-986205Track 2: Nivolumab + RucaparibTrack 2: Ipilimumab + RucaparibTrack 2: Nivolumab + Ipilimumab + RucaparibTotal
White221932776132919413162
Black or African American0010100230119
Asian1210002120009
American Indian or Alaska Native0010000000001
Native Hawaiian or Other Pacific Islander0000001000001
Other0120002001006
Not reported0010001000002
08

Study locations

35 sites
  • Mayo Clinic Arizona
    Phoenix, Arizona 85054, United States
  • Local Institution - 0020
    Duarte, California 91010-3000, United States
  • University Of Colorado
    Aurora, Colorado 80045, United States
  • Local Institution - 0032
    New Haven, Connecticut 06520, United States
  • Local Institution - 0036
    Washington, District of Columbia 20007, United States
  • UF Health Medical Oncology - Davis Cancer Pavilion
    Gainesville, Florida 32610, United States
  • Local Institution - 0038
    Jacksonville, Florida 32224, United States
  • Local Institution - 0006
    Baltimore, Maryland 21224, United States
  • Local Institution - 0017
    Rochester, Minnesota 55905, United States
  • Local Institution - 0003
    Saint Louis, Missouri 63110, United States
  • Local Institution - 0001
    Hackensack, New Jersey 07601, United States
  • Local Institution - 0007
    New York, New York 10065, United States
  • Local Institution - 0002
    Portland, Oregon 97225, United States
  • Local Institution - 0005
    Philadelphia, Pennsylvania 19111, United States
  • UPMC
    Pittsburgh, Pennsylvania 15232, United States
  • Local Institution - 0004
    Seattle, Washington 98109, United States
  • Local Institution - 0035
    Westmead, New South Wales 2145, Australia
  • Local Institution - 0033
    Heidelberg, Victoria 3084, Australia
  • Local Institution
    Randwick, 2031, Australia
  • Local Institution
    Edmonton, Alberta T6G 1Z2, Canada
  • Local Institution
    Vancouver, British Columbia V5Z 4E6, Canada
  • Local Institution
    Ottawa, Ontario K1H 8L6, Canada
  • Local Institution - 0025
    Toronto,, Ontario M4N 3M5, Canada
  • Local Institution - 0021
    Toronto, Ontario M5G 2M9, Canada
  • Local Institution - 0039
    Heidelberg, 69120, Germany
  • Local Institution - 0043
    Leipzig, 04103, Germany
  • Local Institution
    Ramat Gan, 52621, Israel
  • Local Institution
    Tel Aviv, 64239, Israel
  • Local Institution - 0014
    Milan, Lombardia 20141, Italy
  • IRCCS Istituto Nazionale Tumori Milano
    Milano, 20133, Italy
  • Local Institution
    Amsterdam, 1081 HV, Netherlands
  • Local Institution
    Utrecht, 3584 CX, Netherlands
  • Local Institution - 0050
    Singapore, 169610, Singapore
  • Local Institution - 0041
    Chur, Graubünden (de) 7000, Switzerland
  • Local Institution - 0042
    Zuerich, 8091, Switzerland
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in May 2022, 65 months.

Results were first posted in Jun 2023, 1 year after primary completion.

Of 65 industry-sponsored phase 2 interventional studies under Stomach Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 68. This study's 65 months is above that.

Counting every sponsor, half of 360 studies reached it within 50 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2016
First posted
Oct 17, 2016
StartActual
Nov 29, 2016
Primary completionActual
May 11, 2022
CompletionActual
May 11, 2022
Results first posted
Jun 9, 2023
Last update
Jun 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02935634
Collaborators
Clovis Oncology, Inc.
Responsible party
Sponsor
First posted
Oct 17, 2016
Start date
Nov 29, 2016
Primary completion
May 11, 2022
Completion
May 11, 2022
Results posted
Jun 9, 2023
Last update
Jun 9, 2023

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Relatlimab · Linrodostat · Rucaparib

Start the discussion